The Preclinical Modeling shared resource at Fred Hutch is a core that supports the development and maintenance of preclinical mouse models, including patient-derived xenografts (PDX), cell-line xenografts and genetically engineered mouse models (GEMM). We work with investigators in the Fred Hutch/University of Washington Cancer Consortium and other institutions to enable preclinical research on cancer and other diseases.
Our PDX experts have created xenograft models of dozens of cancers, including Merkel cell carcinoma and cancers of the liver, bladder, lung and pancreas, on behalf of investigators across Seattle and beyond. The NSG and NSG hprt-null breeding colony we maintain guarantees mice are always available for PDX implants, and we’ve performed more than 2,000 xenograft surgeries since 2016.
Our GEMM team designs, produces and maintains transgenic and gene-edited mice in partnership with investigators pursuing a variety of research questions. Our high editing efficiency — up to 100% of live-born pups in our projects exhibit successful gene targeting — is testament to our expertise in CRISPR/Cas9 and other state-of-the-art genome engineering technologies.
The comprehensive, specialized services provided to investigators by the experts on our PDX and GEMM teams begin with experimental consultation, followed by sourcing, generation or resuscitation of models, animal care, regulatory support, dosing and sample collection support, tissue banking and more.